Gilead Sciences, Inc. (NASDAQ: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $4 billion in an underwritten, registered public offering, consisting of three tranches:
- $500 million of 2.050% senior notes maturing in April 2019
- $1,750 million of 3.700% senior notes maturing in April 2024
- $1,750 million of 4.800% senior notes maturing in April 2044
The senior notes are rated A- by Standard & Poor's and Baa1 by Moody's. The offering is expected to close March 7, 2014, subject to customary closing conditions.
Gilead intends to use the net proceeds from this offering for general corporate purposes, which may include the repayment of certain of our indebtedness, debt-related payments, working capital and the repurchase of our outstanding common stock pursuant to our authorized share repurchase program.
Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities LLC, Goldman, Sachs & Co. and Wells Fargo Securities, LLC acted as joint book-running managers in the offering. The offering of the securities is being made only by means of a prospectus supplement and the accompanying base prospectus, which is filed as part of Gilead's effective shelf registration statement on Form S-3 (File No. 194298) copies of which may be obtained from:
Merrill Lynch, Pierce, Fenner & Smith Incorporated
J.P. Morgan Securities LLC
|222 Broadway, 11th Floor||383 Madison Ave,|
|New York, NY 10038||New York, NY 10179|
|Attention: Prospectus Department||Attn: Investment Grade Syndicate Desk|
|(800) 294-1322||(212) 834-4533|